Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

1CheckMate 459, 20191IMbrave-150, 2020atezolizumab plus bevacizumab vs. nivolumab alone atezolizumab plus bevacizumab better 0.68 [0.48; 0.98]0.68 [0.48;0.98]atezolizumab plus bevacizumab vs. nivolumab alone atezolizumab plus bevacizumab better 0.68 [0.48; 0.98]atezolizumab plus bevacizumab vs. sorafenib atezolizumab plus bevacizumab better 0.58 [0.42; 0.80]0.58 [0.42;0.80]atezolizumab plus bevacizumab vs. sorafenib atezolizumab plus bevacizumab better 0.58 [0.42; 0.80]nivolumab alone vs. atezolizumab plus bevacizumab atezolizumab plus bevacizumab better 1.47 [1.02; 2.10]1.47 [1.02;2.10]nivolumab alone vs. atezolizumab plus bevacizumab atezolizumab plus bevacizumab better 1.47 [1.02; 2.10]nivolumab alone vs. sorafenib 0.85 [0.71; 1.01]0.85 [0.71;1.01]nivolumab alone vs. sorafenib 0.85 [0.71; 1.01]sorafenib vs. atezolizumab plus bevacizumab atezolizumab plus bevacizumab better 1.72 [1.26; 2.36]1.72 [1.26;2.36]sorafenib vs. atezolizumab plus bevacizumab atezolizumab plus bevacizumab better 1.72 [1.26; 2.36]sorafenib vs. nivolumab alone 1.18 [0.99; 1.40]1.18 [0.99;1.40]sorafenib vs. nivolumab alone 1.18 [0.99; 1.40]sorafenibnivolumab aloneatezolizumab plus bevacizumabpembrolizumab plus lenvatinibsintilimabdirect evidencenetwork meta-analysis
T vs. C sorafenibnivolumab aloneatezolizumab plus bevacizumabpembrolizumab plus lenvatinibsintilimab
sorafenib---1.18
0.99; 1.40		1.72
1.26; 2.36		NANA
nivolumab alone0.85
0.71; 1.01		---1.47
1.02; 2.10		NANA
atezolizumab plus bevacizumab0.58
0.42; 0.80		0.68
0.48; 0.98		---NANA
pembrolizumab plus lenvatinibNANANA---NA
sintilimabNANANANA---

pathologies: 131 - treatments: 724 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons